Articles

Messenger ribonucleic acid (mRNA)-4157 is an innovative approach to personalized neoantigen therapy. It utilizes mRNA to enhance the body’s natural immune response against tumor cells by targeting specific mutations unique to each patient. Read More ›

A pediatric hematology/oncology nurse shares her personal experiences witnessing the significant increase in survival of young patients with cancer over the past few decades, preserving her well-being, and making personal connections with her patients and community. Read More ›

Artificial intelligence holds promise for detecting lung cancer if research presented last month at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer is any indicator. Read More ›

Data presented at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer add another piece to the puzzle of people diagnosed with lung cancer who never smoked. Read More ›

Financial advisors are committed to helping individuals and families set and reach their financial goals. Here are some specific ways you can benefit from this professional relationship. Read More ›

Two quadruplet therapies have been approved by the FDA as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) and updated in the NCCN guidelines for the treatment of multiple myeloma. Read More ›

This article summarizes results of the phase 3 IMROZ study, including the frailty subgroup analysis. Read More ›

Results of the BENEFIT study provide evidence that a weekly bortezomib regimen in isatuximab plus bortezomib, lenalidomide, and dexamethasone can be an effective and feasible option for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). Read More ›

The results of CEPHEUS support the use of daratumumab-based quadruplet therapy for transplant-ineligible or -deferred newly diagnosed multiple myeloma (NDMM). Read More ›